knowledge -WSS

knowledge

author：knowledge 2025-10-01 11:46:03 - browse：54274

ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Study: Adult vaccinations pay for themselves in societal benefits

WSS

Dairy farmers resist CDC push for PPE against bird flu virus

Masked men burn a market in a Mexican city plagued by gang violence, killing 9 people

How redistricting in 6 states could affect who controls Congress

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Study: People of West African ancestry at greater risk of cardiac amyloidosis

Bird flu outbreak in cows is latest avian flu curveball

leisure time

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Walensky prepares to leave CDC — and Congress — behind

Google says AlphaFold 3 can map a vast universe of biomolecules

Virginia high school admissions case could be legal follow

Submersible on Titanic tour reported missing off Newfoundland with 5 people aboard

How to save PrEP access — and even expand it

It shouldn't be easy to buy synthetic DNA to recreate a deadly virus

Moonlake's readout produced a cash windfall. Risks remain

Zelenskyy on how Russian invasion may end, gratitude for US aid and Putin's weakness

Drug repurposing or repositioning? The language matters

Readout LOUD podcast: What to know about H5N1 bird flu

hotspot

The PBM ad wars are taking over Washington, D.C.

Kansas must stop changing trans people's sex listing on driver's licenses, judge says

Google says AlphaFold 3 can map a vast universe of biomolecules

How to improve immunocompromised access to mAb treatments

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

How to improve immunocompromised access to mAb treatments

entertainment

focus

hotspot

entertainment